

8th InterAmerican Oncology Conference

'Current Status and Future of Anti-Cancer Targeted Therapies'

October 17-18, 2019

Buenos Aires, Argentina

FIRST ANNOUNCEMENT

The 8th Conference of IAOC "**Current Status and Future of Anti-Cancer Targeted Therapies**" will be held in Buenos Aires, Argentina in October 17th and 18th, 2019.

An outstanding faculty of speakers from the United States and Europe has committed in this meeting. The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

This meeting is the primary opportunity for oncologists, hematologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.

CO- CHAIRS

Alex Adjei, Rochester, USA

Román Pérez Soler, New York, USA

Antoni Ribas, Los Angeles, USA

ORGANIZING COMMITTEE

Román Pérez Soler, New York, USA

Andrea Blanco, Buenos Aires, Argentina

SCIENTIFIC COMMITTEE

Alex Adjei, M.D., Ph.D., Mayo Clinic, Rochester, USA

Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA

Carlos L. Arteaga, M.D., Harold C. Simmons Cancer Center, Texas, USA

Roman Perez Soler, M.D., Albert Einstein College of Medicine, New York, USA

Antoni Ribas, M.D., Ph.D., UCLA, Los Angeles, USA

Josep Taberner, M.D., Ph.D., Vall d'Hebron University Hospital, Barcelona, Spain

FACULTY (PROVISIONARY)**Alex A. Adjei, M.D., Ph.D.**

Consultant in Oncology
Professor of Oncology
Mayo Clinic
Rochester, Minnesota, USA

Kenneth C. Anderson, M.D.

Kraft Family Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Stephen M. Ansell, M.D., Ph.D.

Professor of Medicine
Chair Lymphoma Group
Mayo Clinic
Rochester, Minnesota, USA

Carlos L. Arteaga, M.D.

Professor of Medicine and Cancer Biology
Professor of Medicine
Director, UTSW Harold C. Simmons Cancer Center
Associate Dean of Oncology
Lisa K. Simmons Distinguished Chair in Comprehensive Oncology
Dallas, Texas, USA

Carlos H. Barrios, M.D.

Hospital do Cancer Mãe de Deus
Porto Alegre RS, Brazil

Joaquim Bellmunt, M.D., Ph.D.

Associate Professor, Medicine,
Harvard Medical School
Bladder Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Jorge Cortés, M.D.

Professor of Medicine
Chief, CML & AML Sections
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas, USA

Charles Drake, M.D., Ph.D. *

Professor of Medicine
Co-Director, Cancer Immunotherapy Programs
Director of genitourinary oncology
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
NY, New York, USA

Román Pérez-Soler, M.D.

Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, , New York, USA

Gabriel A. Rabinovich, Ph.D. *

Head of the Laboratoy of Immunopathology
Instituto de Biología y Medicina Experimental (IBYME)
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
Member of the USA National Academy of Sciences
Buenos Aires, Argentina

Antoni Ribas, M.D., Ph.D.

Professor of Medicine and Surgery
Professor of Molecular and Medical Pharmacology
Director Tumor Immunology Program, Jonsson
Comprehensive Cancer Center (JCCC)
David Geffen School of Medicine, UCLA
Chair, Melanoma Committee at SWOG
Los Angeles, California, USA

Josep Tabernero, M.D., Ph.D.,

Chairman Medical Oncology Department
Vall d'Hebron University Hospital
Barcelona, Spain

*TBC (to be confirmed)

PRELIMINARY PROGRAM

NEW ANTICANCER THERAPIES

- **Promising Novel Agents in Early Clinical Trials:**
Alex A. Adjei, Rochester, USA
- **Novel Combination Approaches for Cancer Immunotherapy:**
TBA
- **Immune Checkpoint Inhibitors for Melanoma:**
Antoni Ribas, California, USA
- **Emerging Checkpoints in Immune and Vascular Signaling Programs in Cancer:**
Gabriel Rabinovich, Buenos Aires, Argentina (*TBC)
- **Cancer Biomarkers:**
Antoni Ribas, California, USA
- **The Evolution of Cancer Immunotherapy:**
Ignacio Melero, Pamplona, Spain (*TBC)

BREAST CANCER

- **New Drugs and treatments in Breast Cancer:**
Carlos L. Arteaga, Texas, USA
- **Challenges in the Genomic Selection of Patients:**
Carlos Barrios, Porto Alegre, Brazil

GU CANCER

- **Novel Therapies in Prostate and Renal Cancer:**
Charles Drake, Columbia, USA (*TBC)
- **The Evolution of Targeted Therapy and Checkpoint Inhibitors in Bladder Cancer:**
Joaquim Bellmunt, Barcelona, Spain

GI CANCER

- **Novel Therapies in Gastric Cancer:**
Josep Taberero, Barcelona, Spain

- **New Treatment for Colorectal Cancer:**
Josep Taberner, Barcelona, Spain

LUNG CANCER

- **What's new in the Management of SCLC:**
Alex A. Adjei, Rochester, USA
- **Current Management of NSCLC:**
Román Pérez Soler, New York, USA
- **Combination Immunotherapy for Lung Cancer:**
TBA

HEMATOLOGICAL MALIGNANCIES

- **New Developments in Lymphoma:**
Stephen Ansell, Rochester, USA
- **Multiple Myeloma:**
Kenneth C. Anderson, Boston, USA
- **Novel Drug Development in Leukemia:**
Jorge Cortés, Houston, USA

CONFERENCE SECRETARIAT AND INFORMATION

E-mail: secretariat@oncologyconferences.com.ar

Web: www.oncologyconferences.com.ar